ReviewTranslational cancer research2026
Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major global health burden with unsatisfactory overall prognosis, largely attributed to profound heterogeneity, late-stage diagnosis, and therapeutic resistance. Over the past decade, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have reshaped treatment paradigms, yet durable responses remain limited to a subset of patients, underscoring the need for deeper mechanistic understanding and refined therapeutic strategies. In 2025, transformative advances in translational research have reshaped the landscape of GC immuno-oncology, moving toward mechanism-driven precision medicine. This review synthesizes key breakthroughs across interconnected domains, including multidimensional predictive biomarker systems, emerging immunoregulatory targets beyond classical checkpoints, advanced immunotherapeutic technologies such as adoptive cell transfer (ACT) and cancer vaccines, and the intertwined networks of tumor microenvironment (TME) remodeling and metabolic reprogramming. Notably, advances in understanding myeloid cell subset heterogeneity [e.g., myelocyte and metamyelocyte-stage (MC&MM-stage) neutrophils] and the development of major histocompatibility complex class II (MHC-II)-restricted neoantigen vaccines have further deepened mechanistic insights and expanded the therapeutic toolkit. These collective progressions have established a cohesive "mechanism-biomarker-therapy" loop, laying the foundation for personalized combination strategies. Despite significant advances, challenges persist-including tumor heterogeneity, immunosuppressive TME, and the need to balance therapeutic efficacy with toxicity. Future directions should leverage multi-omics and artificial intelligence to optimize personalized combination therapies, advance precise perioperative interventions for early-stage GC, and implement dynamic treatment adjustments, ultimately improving therapeutic efficacy and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.